RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board
RhoVac AB ("RhoVac") announces today September 4th 2020, that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing Professor Georg Holländer, Action Research Professor and Head of Department at Oxford University, UK and Professor in Development Immunology, ETH Zurich, Switzerland, and Pediatric Immunology, University of Basel, Switzerland to the Scientific Advisory Board. Professor Holländer is also Director of the Botnar Research Center for Child Health (BRCCH) in Basel, Switzerland.
Professor Georg Holländer, MD, PhD, joins RhoVac Scientific Advisory Board with an extensive experience in immunology, were his specific scientific focus concerns the molecular and cellular control of thymus development and function. After his Medical Studies at Basel University, he proceeded his postdoctoral research at Harvard Medical School, Boston, U.S. and held an Assistant Professor before returning to Switzerland. He was then appointed Full Professor in Molecular Medicine in Pediatrics 2003 at Basel University and held several academic positions there including Head of Research at the Basel University Childrens’ Hospital. In 2010, he was appointed as Action Research Professor of Paediatrics, University of Oxford, UK and in 2020 as full Professor in Developmental Immunology at Eidgenössische Technische Hochschule (ETH) in Zürich, Switzerland.
CEO Anders Månsson comments: “We are excited and proud that Professor Holländer, as a renowned expert in the field, wants to join our Scientific Advisory Board. With this recruitment, as well as the earlier ScientificAdvisory Board recruitments of prominent expertise, both pre-clinically and clinically, we now conclude that RhoVac has a scientific team in place that will enable us to stand toe to toe with the potential partners for RV001.
For further information, please contact:
Anders Månsson – CEO, RhoVac AB
Phone number: +46 73-751 72 78
This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 4th September 2020.
About RhoVac AB
RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is launching a clinical phase IIb trial that will include at least 175 prostate cancer patients. The study is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com